Adverse Event Reports Rising Faster Than FDA Adds Surveillance Staff
This article was originally published in The Tan Sheet
Executive Summary
Adverse event reports submitted each year have quadrupled over the last decade, and FDA expects the reports to retain their value in ensuring product safety even as more technology helps with drug safety monitoring.
You may also be interested in...
FDA’s Sentinel Likely To Outpace Traditional Post-Market Studies, But Will It Replace Them?
Pilot project for overactive bladder drug Mybretriq raises questions as to how Sentinel will affect sponsor’s risk-monitoring obligations.
AER Label Guidance Holds To Requiring Full Addresses For OTCs, Supplements
FDA is extending the deadline for serious adverse event labeling requirements for OTC drugs and dietary supplements until January 2010 because it has yet to finalize its guidance to comply with those regulations
Pink Sheet Podcast: US FDA Loses Gene Therapy Expert, Humira Biosimilars Launch, FDA Allows In-Person Meetings
Pink Sheet reporters and editors consider the impact of FDA Office of Tissues and Advanced Therapies Director Wilson Bryan’s retirement, the launch of Humira biosimilars and its effect on the biologic market, as well as the FDA moving to hybrid meetings with sponsors.